Warning: Thalidomide-related thrombotic risk potentially concerns patients with lupus

Lupus

Volumn 11, Issue 2, 2002, Pages 67-70

  Piette, J C ^a   Sbai A ^a   Frances C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; THALIDOMIDE;

ANGIOGENESIS; DISCOID LUPUS ERYTHEMATOSUS; EDITORIAL; HUMAN; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN LUPUS ERYTHEMATOSUS; THROMBOSIS; VEIN THROMBOSIS;

HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; RISK ASSESSMENT; THALIDOMIDE; THROMBOSIS;

EID: 0036201780     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu180ed     Document Type: Editorial

References (38)

1. Thalidomide current and potential clinical applications
2. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
3. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus
4. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy
5. Update on therapy - Thalidomide in the treatment of lupus
6. Early fœtal thrombosis induced by thalidomide in mouse: Possible explanation of teratogenicity
7. Traitement de l'aphthose par la thalidomide et la colchicine
8. Thalidomide et thromboses
9. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
10. Deep venous thrombosis and thalidomide therapy for multiple myeloma
11. Thalidomide and thrombosis in patients with multiple myeloma
12. Thalidomide et thromboses: Trois observations
13. Thrombose veineuse et embolie pulmonaire au cours d'une aphtose traitée par thalidomide
14. Thalidomide in the treatment of mucocutaneous lesions of the Behcet's syndrome: A randomized, double blind, placebo-controlled trial
15. Thalomid (Thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing
16. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
17. Thalidomide is an inhibitor of angiogenesis
18. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
19. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment
20. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus
21. Thrombosis and systemic lupus erythematosus: The Hopkins Lupus Cohort perspective
22. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
23. Systemic lupus erythematosus and the skin
24. The use of exogenous estrogens, endocrine system, and urogenital tract
25. Contraceptive practice in women with systemic lupus erythematosus
26. Epidemiology of the antiphospholipid antibody syndrome
27. Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus
28. Anticardiolipin-Antikörper beim kutanen Lupus erythematodes
29. Anticardiolipin and antinuclear antibodies in discoid lupus erythematosus - Their clinical significance
30. Kutaner Lupus erythematodes fund Kardiolipin-Antikörper
31. Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus
32. Discoid lupus erythematosus associated with the anticardiolipin syndrome
33. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases
34. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
35. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
36. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
37. Contraception in women at high risk or with established cardiovascular disease
38. Pregnane progestin is a safe contraception in patients with systemic lupus erythematosus